Techno Medica Co., Ltd.
Notice regarding the Revision of Earnings Guidance for the Second Quarter of the Fiscal Year Ending March 2027
Earnings guidance for the second quarter of the fiscal year ending March 2027 has been revised upward. Revenue 4,360 million yen from 4,270 million yen, operating income 300 million yen from 170 million yen, ordinary income 310 million yen from 170 million yen, and net income for the period attributable to owners of parent 220 million yen from 120 million yen. Increases of 90 million yen, 130 million yen, 140 million yen, and 100 yen in per-share interim net income, respectively. Main reasons: higher sales of consumables both domestically and internationally and reduced selling, general and administrative expenses due to delayed recognition of R&D costs. No impact on full-year guidance. No change to dividend guidance.
Key Figures
- Revenue: 4,360百万円（対前回比+2.1%）
- Operating income: 300百万円（対前回比+130百万円）
- Ordinary income: 310百万円（対前回比+140百万円）
AI要約
Overview of earnings guidance revision
We revised the earnings guidance for the second quarter of the fiscal year ending March 2027 (April 1, 2026–September 30, 2026). All metrics—revenue, operating income, ordinary income, interim net income, and interims per-share net income—are upwardly revised, with particularly notable growth in operating income, ordinary income, and interim net income. The revision is primarily due to increased sales of consumables domestically and internationally and reduced SG&A expenses due to delayed recognition of R&D costs, and is not expected to affect the full-year earnings guidance. There is no change to the dividend guidance.
Outlook and notes
The revision applies only to the interim period, with no impact anticipated on the full-year guidance. While exchange rates at the time of disclosure are cited, the body does not include specific explanations of currency impact. Future performance may be influenced by market trends, timing of R&D costs, and promotional activities.
TechnoMedica Co., Ltd.
Company overview · Stock price · Financial data · All IR
